Richter's Transformation

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Ono PharmaceuticalJapan - Osaka

1 program

ONO-4538Phase 21 trial

Active Trials

NCT06936943Recruiting14Est. Jul 2030

SanofiPARIS, France

1 program

OxaliplatinPHASE_1_21 trial

Active Trials

NCT00472849Completed92Est. Feb 2012

GSKLONDON, United Kingdom

1 program

PNT2258PHASE_21 trial

Active Trials

NCT02378038Terminated5Est. Jun 2016

Karyopharm TherapeuticsNEWTON, MA

1 program

selinexorPHASE_21 trial

Active Trials

NCT02138786Terminated27Est. Aug 2016

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Ono PharmaceuticalONO-4538

GSKPNT2258

Karyopharm Therapeuticsselinexor

SanofiOxaliplatin

Clinical Trials (4)

Total enrollment: 138 patients across 4 trials

NCT06936943 Ono PharmaceuticalONO-4538

ONO-4538 Study in Patients With Richter's Transformation

Start: Nov 2025Est. completion: Jul 203014 patients

Phase 2Recruiting

NCT02378038 GSKPNT2258

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Start: Aug 2015Est. completion: Jun 20165 patients

Phase 2Terminated

NCT02138786 Karyopharm Therapeuticsselinexor

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

Start: Nov 2014Est. completion: Aug 201627 patients

Phase 2Terminated

NCT00472849 SanofiOxaliplatin

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Start: May 2007Est. completion: Feb 201292 patients

Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 138 patients

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.